Pharmacology of therapeutic botulinum toxin preparations

References

• Kerner J. Vergiftung durch verdorbene Würste. Tübinger Blätter f Naturwissensch u Arzneykunde 1817; 3: 1–25
   Google Scholar
• Kerner J. Neue Beobachtungen über die in Würthemberg so häufig vorfallenden tödlichen Vergiftungen durch den Genuß geräucherter Würste. GF Osiander, Tübingen 1820
   Google Scholar
• Kerner J. Das Fettgift und die Fettsäure und ihre Wirkungen auf den thierischen Organismus. Ein Beytrag zur Untersuchung des in verdorbenen Würsten giftig wirkenden Stoffes. Cotta-Verlag, Stuttgart und Tübingen 1822
   Google Scholar
• Schantz E J. Historical perspective. Therapy with Botulinum toxin, J Jankovic, M Hallett. Marcel Dekker, Inc., New York, Basel, Hong Kong 1994; XXIII–XXVI
   Google Scholar
• Scott A B, Rosenbaum A, Collins C C. Pharmacologic weakening of extraocular muscles. Invest Ophthalmol 1973; 12: 924–927
   PubMedGoogle Scholar
• Scott A B. Foreword. Therapy with Botulinum toxin, J Jankovic, M Hallett. Marcel Dekker, Inc., New York, Basel, Hong Kong 1994; VII–IX
   Google Scholar
• Scott A B. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. J Pediatr Ophthalmol Strabismus 1980; 17: 21–25
   PubMed Web of Science ®Google Scholar
• Dressler D, Benecke R, Conrad B. Botulinum-Toxin in der Therapie kraniozervikaler Dystonien. Nervenarzt 1989; 60: 386–394
   PubMed Web of Science ®Google Scholar
• Dressler D. Botulinum Toxin Therapy. Thieme Verlag, Stuttgart, New York 2000
   Google Scholar
• Pellizzari R, Rossetto O, Schiavo G, Montecucco C. Tetanus and botulinum neurotoxins: Mechanism of action and therapeutic uses. Philos Trans R Soc Lond B Biol Sci 1999; 354: 259–268
   PubMed Web of Science ®Google Scholar
• Schiavo G, Santucci A, Dasgupta B R, Mehta P P, Jontes J, Benfenati F, Wilson M C, Montecucco C. Botulinum neurotoxins serotypes A and E cleave SNAP-25 at distinct COOH-terminal peptide bonds. FEBS Lett 1993; 335: 99–103
   PubMed Web of Science ®Google Scholar
• Binz T, Blasi J, Yamasaki S, Baumeister A, Link E, Sudhof T C, Jahn R, Niemann H. Proteolysis of SNAP-25 by types E and A botulinal neurotoxins. J Biol Chem 1994; 269: 1617–1620
   PubMed Web of Science ®Google Scholar
• Foran P, Lawrence G W, Shone C C, Foster K A, Dolly J O. Botulinum neurotoxin C1 cleaves both syntaxin and SNAP-25 in intact and permeabilized chromaffin cells: Correlation with its blockade of catecholamine release. Biochemistry 1996; 35: 2630–2636
   PubMed Web of Science ®Google Scholar
• Schiavo G, Benfenati F, Poulain B, Rossetto O, Polverino de Laureto P, Das-Gupta B R, Montecucco C. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 1992; 359: 832–835
   PubMed Web of Science ®Google Scholar
• Yamasaki S, Baumeister A, Binz T, Blasi J, Link E, Cornille F, Roques B, Fykse E M, Sudhof T C, Jahn R. Cleavage of members of the synaptobrevin/VAMP family by types D and F botulinal neurotoxins and tetanus toxin. J Biol Chem 1994; 269: 12764–12772
   PubMed Web of Science ®Google Scholar
• Duchen L W. An electron microscopic study of the changes induced by botulinum toxin in the motor end-plates of slow and fast skeletal muscle fibres of the mouse. J Neurol Sci 1971; 14: 47–60
   PubMed Web of Science ®Google Scholar
• Duchen L W. Changes in the electron microscopic structure of slow and fast skeletal muscle fibres of the mouse after the local injection of botulinum toxin. J Neurol Sci 1971; 14: 61–74
   PubMed Web of Science ®Google Scholar
• de Paiva A, Meunier F A, Molgo J, Aoki K R, Dolly J O. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: Biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci USA 1999; 96: 3200–3205
   PubMed Web of Science ®Google Scholar
• Brin M F, Dressler D, Aoki R. Pharmacology of botulinum toxin therapy. Dystonia: Etiology, clinical features, and treatment, J Jankovic, C Comella, M F Brin. Lippincott Williams & Wilkins, Philadelphia 2004; 93–112
   Google Scholar
• Dressler D, Rothwell J C. Electromyographic quantification of the paralysing effect of botulinum toxin. Eur Neurol 2000; 43: 13–16
   PubMed Web of Science ®Google Scholar
• Dressler D, Rothwell J C, Bigalke H. The sternocleidomastoid test: An in vivo assay to investigate botulinum toxin antibody formation in man. J Neurol 2000; 247: 630–632
   PubMed Web of Science ®Google Scholar
• Filippi G M, Errico P, Santarelli R, Bagolini B, Manni E. Botulinum A toxin effects on rat jaw muscle spindles. Acta Otolaryngol 1993; 113: 400–404
   PubMed Web of Science ®Google Scholar
• Dressler D, Eckert J, Kukowski B, Meyer B U. Somatosensorisch Evozierte Potentiale bei Schreibkrampf: Normalisierung pathologischer Befunde unter Botulinum Toxin Therapie. Z EEG EMG 1993; 24: 191
   Google Scholar
• Rosales R L, Arimura K, Takenaga S, Osame M. Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection. Muscle Nerve 1996; 19: 488–496
   PubMed Web of Science ®Google Scholar
• Kaji R, Kohara N, Katayama M, Kubori T, Mezaki T, Shibasaki H, Kimura J. Muscle afferent block by intramuscular injection of lidocaine for the treatment of writer's cramp. Muscle Nerve 1995; 18: 234–235
   PubMed Web of Science ®Google Scholar
• Kaji R, Rothwell J C, Katayama M, Ikeda T, Kubori T, Kohara N, Mezaki T, Shibasaki H, Kimura J. Tonic vibration reflex and muscle afferent block in writer's cramp. Ann Neuro 1995; 138: 155–162
   Web of Science ®Google Scholar
• Wiegand H, Erdmann G, Wellhoner H H. 125I-labelled botulinum A neurotoxin: Pharmacokinetics in cats after intramuscular injection. Naunyn Schmiedebergs Arch Pharmacol 1976; 292: 161–165
   PubMed Web of Science ®Google Scholar
• Takamizawa K, Iwamori M, Kozaki S, Sakaguchi G, Tanaka R, Takayama H, Nagai Y. TLC immunostaining characterization of Clostridium botulinum type A neurotoxin binding to gangliosides and free fatty acids. FEBS Lett 1986; 201: 229–232
   PubMed Web of Science ®Google Scholar
• Sanders D B, Massey E W, Buckley E G. Botulinum toxin for blepharospasm: single-fibre EMG studies. Neurology 1986; 36: 545–547
   PubMed Web of Science ®Google Scholar
• Lange D J, Brin M F, Warner C L, Fahn S, Lovelace R E. Distant effects of local injection of botulinum toxin. Muscle Nerve 1987; 10: 552–555
   PubMed Web of Science ®Google Scholar
• Olney R K, Aminoff M J, Gelb D J, Lowenstein D H. Neuromuscular effects distant from the site of botulinum neurotoxin injection. Neurology 1988; 38: 1780–1783
   PubMed Web of Science ®Google Scholar
• Girlanda P, Vita G, Nicolosi C, Milone S, Messina C. Botulinum toxin therapy: Distant effects on neuromuscular transmission and autonomic nervous system. J Neurol Neurosurg Psychiatry 1992; 55: 844–845
   PubMed Web of Science ®Google Scholar
• Dressler D, Benecke R. Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis. Eur Neurol 2003; 49: 34–38
   PubMed Web of Science ®Google Scholar
• Ishikawa H, Mitsui Y, Yoshitomi T, Mashimo K, Aoki S, Mukuno K, Shimizu K. Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. Jpn J Ophthalmol 2000; 44: 106–109
   PubMed Web of Science ®Google Scholar
• Purkiss J, Welch M, Doward S, Foster K. Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: Involvement of two distinct mechanisms. Biochem Pharmacol 2000; 59: 1403–1406
   PubMed Web of Science ®Google Scholar
• Welch M J, Purkiss J R, Foster K A. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 2000; 38: 245–258
   PubMed Web of Science ®Google Scholar
• Cui M, Li Z, You S, Khanijou S, Aoki R. Mechanisms of the antinociceptive effect of subcutaneous Botox: inhibition of peripheral and central nociceptive processing. Arch Pharmacol 2002; 365: R17
   Web of Science ®Google Scholar
• McMahon H, Foran P, Dolly J. Tetanus toxin and botulinum toxins type A and B inhibit glutamate, gamma-aminobutyric acid, aspartate, and met-enkephalin release from synaptosomes: clues to the locus of action. J Biol Chem 1992; 267: 21338–21343
   PubMed Web of Science ®Google Scholar
• Morris J, Jobling P, Gibbins I. Differential inhibition by botulinum neurotoxin A of cotransmitters released from autonomic vasodilator neurons. Am J Physiol Heart Circ Physiol 2001; 281: 2124–2132
   Web of Science ®Google Scholar
• Shone C C, Melling J. Inhibition of calcium-dependent release of noradrenaline from PC12 cells by botulinum type-A neurotoxin. Long-term effects of the neurotoxin on intact cells. Eur J Biochem 1992; 207: 1009–1016
   PubMedGoogle Scholar
• Dressler D, Adib Saberi F, Benecke R. Botulinum toxin type B for treatment of axillary hyperhidrosis. J Neurol 2002; 249: 1729–1732
   PubMed Web of Science ®Google Scholar
• Benecke R, Jost W H, Kanovsky P, Ruzicka E, Comes G, Grafe S. A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology 2005; 64: 1949–1951
   PubMed Web of Science ®Google Scholar
• Dressler D, Adib Saberi F. Safety aspects of high dose Xeomin® therapy. J Neurol 2006; 253(Suppl. 2)II/141
   Google Scholar
• Dressler D, Dirnberger G. Botulinum toxin therapy: Risk factors for therapy failure. Mov Disord 2000; 15(suppl. 2)51
   Google Scholar
• Dressler D. Immunological aspects of botulinum toxin therapy. Neurology, in press
   Web of Science ®Google Scholar
• Jankovic J, Vuong K D, Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 2003; 60: 1186–1188
   PubMed Web of Science ®Google Scholar
• Pickett A, Panjwani N, O'Keeffe R S. Potency of Type A Botulinum toxin preparations in clinical use. 40th Annual Meeting of the Interagency Botulism Research Coordinating Committee (IBRCC), AtlantaUSA, Nov., 2003
   Google Scholar
• Settler P. The biochemistry of botulinum toxin type B. Neurology 2000; 55(Suppl. 5)S22–28
   PubMed Web of Science ®Google Scholar
• Dressler D, Benecke R. Xeomin® eine neue therapeutische Botulinum Toxin Typ A-Präparation. Akt Neurol 2006; 33: 138–141
   Web of Science ®Google Scholar
• Dressler D. Complete secondary botulinum toxin therapy failure in blepharospasm. J Neurol 2000; 247: 809–810
   PubMed Web of Science ®Google Scholar
• Dressler D. New formulation of BOTOX®: Complete antibody-induced therapy failure in hemifacial spasm. J Neurol 2004; 251: 360
   PubMed Web of Science ®Google Scholar
• Probst T E, Heise H, Heise P, Benecke R, Dressler D. Rare immunologic side effects of botulinum toxin therapy: brachial plexus neuropathy and dermatomyositis. Mov Disord 2002; 17(suppl. 5)S49
   Google Scholar
• Erbguth F, Claus D, Engelhardt A, Dressler D. Systemic effect of local botulinum toxin injections unmasks subclinical Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiat 1993; 56: 1235–1236
   PubMed Web of Science ®Google Scholar
• Dressler D. Dysport produces intrinsically more swallowing problems than Botox: Unexpected results from a conversion factor study in cervical dystonia. J Neurol Neurosurg Psychiatry 2002; 73: 604
   PubMed Web of Science ®Google Scholar
• Dressler D, Eleopra R. Clinical use of non-A botulinum toxins: Botulinum toxin type B. Neurotox Res 2006; 9: 121–125
   PubMed Web of Science ®Google Scholar